期刊文献+

刺桐胰蛋白酶抑制剂突变体在大肠杆菌中表达及在tPA纯化中的应用 被引量:2

Expression of Erythrina Trypsin Inhibitor Mutant rserETI in E. coli and Application of Expressed Product in Purification of Recombinant tPA
下载PDF
导出
摘要 目的构建刺桐胰蛋白酶抑制剂突变体(rserETI)原核表达载体,制备表达产物,用于tPA的纯化。方法设计合成rserETI编码序列DNA片段,以PCR法扩增出全长编码区序列,经酶切后克隆至pET9a表达载体,转化大肠杆菌JM109DE3,以IPTG诱导表达。表达产物经变性、复性、QFF层析纯化后,测定其活性,并与溴化氰活化的Sepharose偶联合成亲和层析柱,纯化rtPA。结果rserETI的表达量约占大肠杆菌菌体总蛋白的30%,复性率为80%,经QFF层析纯化后,蛋白浓度为1.58mg/ml,SDS-PAGE检测显示无杂蛋白污染,纯度大于95%,对rtPA突变体的抑制比活性为4×104IU/mg。偶联合成的rserETI-Sepharose亲和层析柱能特异性地纯化rtPA,rtPA突变体纯度达96%,比活性为5.07×105IU/mg。结论已成功构建了rserETI原核表达载体,并在大肠杆菌中高效表达,制备的表达产物可用于rtPA的纯化。 Objective To construct a prokaryotic expression vector for erythrina trypsin inhibitor mutant rserETI,express the mutant and apply to the purification of tissue type plasminogen activator(tPA).Methods A gene fragment encoding ETI,with a substitution of amino acid Val at N-terminus to Ser,was designed,based on which twelve primers were synthesized.The full-length DNA sequence encoding rserETI was amplified by PCR using the synthetic primers,digested with restriction endonuclease and cloned into vector pET9a.The constructed recombinant plasmid pET9a/rserETI was transformed to E.coli JM109DE3 for expression under induction of IPTG.The expressed product was refolded,purified by QFF ion exchange chromatography and tested for activity,then coupled to cyanogen bromide-activated Sepharose for purification of recombinant tPA(rtPA)by affinity chromatography.Results The expressed product contained about 30% of total somatic protein,80% of which was refolded.After purification by QFF chromatography,the expressed product reached a protein content of 1.58 mg/ml and a purity of more than 95%.No contaminated foreign protein bands were shown on SDS-PAGE profile.The specific activity of expressed rserETI in inhibiting rtPA mutant was 4×104 IU/mg.The rtPA mutant after purification by rserETI-Sepharose affinity chromatography reached a purity of 96% and a specific activity of 5.07×105 IU/mg.Conclusion The prokaryotic expression vector for rserETI was successfully constructed and highly expressed in E.coli,and the expressed product was suitable for the purification of rtPA.
出处 《中国生物制品学杂志》 CAS CSCD 2007年第11期802-806,共5页 Chinese Journal of Biologicals
关键词 刺桐胰蛋白酶抑制剂 突变体 组织纤溶酶原激活剂 基因克隆 原核表达 纯化 Erythrina trypsin inhibitor Mutant Tissue plasminogen activator Gene cloning Prokaryotic expression Purification
  • 相关文献

参考文献11

  • 1Joubert FJ.Purification and properties of the proteinase inhibitors from Erythrina caffra seed.Int J Biochem,1982,14(3):187-1930.
  • 2Zimmerman M,Quigley JP,Ashe B,et al.Direct fluorescent assay of urokinase and plasminogen activators of normal and malignant cells:kinetica and inhibitor profile.Proc Natl Acad Sci USA,1978,75(2):750-753.
  • 3Heussen C,Joubert FJ,Dowdle EB.Purification of human tissue plasminogen activator with Eryhrina trypsin inhibitors.J Biol Chem,1984,259(1):11635-11638.
  • 4Lehle K,Kohnert U,Stern A,et al.Effect of disulfide bonds on the structure,function,and stability of the trypsin/tPA inhibitor from Erythrina caffra:site-directed mutagenesis,expression,and physiochmical characterization.Nature Biotech,1996,14(4):476-480.
  • 5Minuth T,Kramer B,Lehle K,et al.The spectroscopic analysis,inhibition and binding studies demonstrate the equivalence of Erythrina caffra trypsin inhibitor and the recombinant substitution variant recSerETI,J Biotech,1998,62(3):231 - 239.
  • 6任启生,陈黄实,宋新荣,李伯松.刺桐胰蛋白酶抑制剂基因的构建及表达研究[J].中国生物工程杂志,2003,23(7):102-104. 被引量:4
  • 7李湛勇,史林启,何炳林,梁树人.环氧活化法制备免疫吸附剂及其对乙型肝炎表面抗原的吸附[J].离子交换与吸附,2001,17(3):242-247. 被引量:4
  • 8朱美财,占志,王雅静,刘成刚,石缨,蔡庆.抗PAI抑制作用的组织纤溶酶原激活剂在大肠杆菌中的表达[J].细胞与分子免疫学杂志,2005,21(5):565-569. 被引量:5
  • 9Teixeira AV,Dowdle EBD,Botes DP.Synthesis and expression of a gene coding for Erythrina trypsin inhibitor(ETI).Biochim et Biophys Acta,1994,1217(1):16-22.
  • 10Dix DB,Thompson RC.Codon choice and gene expression:synonymous codon differ in translational accuracy.Proc Natl Acad Sci USA,1989,86(18):6888-6892.

二级参考文献25

  • 1萨姆布鲁克J 弗里奇EF 曼尼阿蒂斯T.《分子克隆实验指南》第2版[M].北京:科学出版社,1992.908.
  • 2Joubert F J. Purification and properties of the proteinase inhibitors from Erythrina caffra seeds. Int J Biochem, 1982,14 : 187 ~ 193.
  • 3Francois J, Joubet E H. The reactive sites of proteinase inhibitors from Erythrna seeds. Int J Biochem, 1987,19 : 601 ~ 606.
  • 4Joubert F J, Doudle E B. The primary structure of the inhibitor of tissue plasminogen activator found in the seeds of Erythrina caffra.Thrombosis and Haemostasis, 1987,57 : 356 ~ 360.
  • 5Minuth T, Kramer B, Lehle K, et al. The spetroscopic analysis inhibition and binding studies demonstrate the equivalence of Erythrina caffra trypsin inhibitor and the recombinant substitution variant recSerETI. Journal of Biotechnology, 1998,62 : 231 ~ 239.
  • 6Heussen C, Joubet F, Dowdle E B. Purification of human tissue plasminogen activator with Erythrina trypsin inhibitor. J Biol Chem, 1984,259 : 11635 ~ 11638.
  • 7Texieira A V, Dowdle E B D, Botes D P. Synthesis and expression of a gene coding for Erythrina trypsin Inhibitor (ETI). Bioehim Biophys Acta, 1994,1217 : 16 ~ 22.
  • 8Lehh K, Kohnert U, Stem A, et al. Effect of disulfide bonds on the structure, function and stability of the trypsin-t-PA inhibitor from Erythrina: site-directed mutagenesis, expression and physiochemical characterization. Nat Biotechnol, 1996,14 : 476 ~ 480.
  • 9Erlanger B, Kokowsky F, Cohen N W. The preparation and properties of two new chromogenic substrates of trypsin. Arch Biochem Biophys, 1961,95:271 ~ 278.
  • 10Walsh K A, Wilcox P E. Serine proteases. Methods Enzymol, 1970,19:31 ~ 41.

共引文献15

同被引文献13

  • 1朱美财,占志,王雅静,刘成刚,石缨,蔡庆.抗PAI抑制作用的组织纤溶酶原激活剂在大肠杆菌中的表达[J].细胞与分子免疫学杂志,2005,21(5):565-569. 被引量:5
  • 2Wooster MB,Luzier AB.Reteplase:a new thrombolytic for the treatment of acute myocardial infarction[J].Ann Pharmacother,1999,33(3):318-324.
  • 3Collen D,Lijnen HR,Todd PA,Goa KL.Tissue-type plas-minogen activator.A review of its pharmacology and ther-apeutic use as a thrombolytic agent[J].Drugs,1989,38(3):346-388.
  • 4Collen D,Lijnen HR.The tissue-type plasminogen activa-tor story[J].Arterioscler Thromb Vasc Biol,2009,29(8):1151-1155.
  • 5Seifried E,Müller MM,Martin U,Knig R,Hombach V.Bolus application of a novel recombinant plasminogen acti-vator in acute myocardial infarction patients:pharmacoki-netics and effects on the hemostatic system[J].Ann N Y Acad Sci,1992,667:417-420.
  • 6Collen D,Lijnen HR.Thrombolytic agents[J].Thromb Haemost,2005,93(4):627-630.
  • 7Kohnert U,Rudolph R,Verheijen JH,Weening-Verhoeff EJ,Stern A,Opitz U,et al.Biochemical properties of the kringle2and protease domains are maintained in the refolded t-PA deletion variant BM06.022[J].Protein Eng,1992,5(1):93-100.
  • 8Horrevoets AJ,Smilde A,de Vries C,Pannekoek H.The specific roles of finger and Kringle2domains of tissue-type plasminogen activator during in vitro fibrinolysis[J].J Biol Chem,1994,269(17):12639-12644.
  • 9Zhang JG,Krajden OB,Kainthan RK,Kizhakkedathu JN,Constantinescu I,Brooks DE,et al.Conjugation to hyper-branched polyglycerols improves RGD-mediated inhibition of platelet function in vitro[J].Bioconjug Chem,2008,19(6):1241-1247.
  • 10Foley JH,Cook PF,Nesheim ME.Kinetics of activated thrombin-activatable fibrinolysis inhibitor(TAFIa)-cata-lyzed cleavage of C-terminal lysine residues of fibrin degra-dation products and removal of plasminogen-binding sites[J].J Biol Chem,2011,286(22):19280-19286.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部